DE60235198D1 - Pyrrolidin-derivatie als prostaglandin-modulatoren - Google Patents
Pyrrolidin-derivatie als prostaglandin-modulatorenInfo
- Publication number
- DE60235198D1 DE60235198D1 DE60235198T DE60235198T DE60235198D1 DE 60235198 D1 DE60235198 D1 DE 60235198D1 DE 60235198 T DE60235198 T DE 60235198T DE 60235198 T DE60235198 T DE 60235198T DE 60235198 D1 DE60235198 D1 DE 60235198D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- disorder
- substituted pyrrolidine
- pyrrolidin derivatives
- prostaglandin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34262001P | 2001-12-20 | 2001-12-20 | |
PCT/EP2002/014593 WO2003053923A2 (en) | 2001-12-20 | 2002-12-19 | Pyrrolidine derivatives as prostaglandin modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60235198D1 true DE60235198D1 (de) | 2010-03-11 |
Family
ID=23342570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60235198T Expired - Lifetime DE60235198D1 (de) | 2001-12-20 | 2002-12-19 | Pyrrolidin-derivatie als prostaglandin-modulatoren |
Country Status (10)
Country | Link |
---|---|
US (3) | US7335680B2 (de) |
EP (1) | EP1458679B1 (de) |
JP (1) | JP4554931B2 (de) |
AT (1) | ATE455758T1 (de) |
AU (2) | AU2002358772B2 (de) |
CA (1) | CA2469075C (de) |
DE (1) | DE60235198D1 (de) |
ES (1) | ES2337887T3 (de) |
IL (2) | IL162602A0 (de) |
WO (1) | WO2003053923A2 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7335680B2 (en) * | 2001-12-20 | 2008-02-26 | Laboratoires Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
AU2003272963A1 (en) | 2002-10-10 | 2004-05-04 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
KR100843244B1 (ko) | 2007-04-19 | 2008-07-02 | 삼성전자주식회사 | 반도체 소자 및 그 제조 방법 |
EP1841733A2 (de) | 2004-11-08 | 2007-10-10 | Allergan, Inc. | Substituierte pyrrolidonverbindungen als prostaglandin-ep4-agonisten |
US7893107B2 (en) | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
US7557095B2 (en) * | 2006-05-12 | 2009-07-07 | Allergan, Inc. | Therapeutic compounds |
US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
AU2008246579A1 (en) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
JP5524047B2 (ja) * | 2007-05-23 | 2014-06-18 | アラーガン インコーポレイテッド | 緑内障および眼圧上昇の治療用環状ラクタム類 |
US7964596B2 (en) | 2008-03-07 | 2011-06-21 | Allergan, Inc. | Therapeutic compounds |
EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
CA2741589A1 (en) * | 2008-11-10 | 2010-05-14 | Pfizer Limited | Pyrrolidines |
WO2010087425A1 (ja) | 2009-01-30 | 2010-08-05 | 国立大学法人京都大学 | 前立腺癌の進行抑制剤および進行抑制方法 |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3873566A (en) * | 1973-02-28 | 1975-03-25 | Du Pont | 3-Pyrazolidinones and pyrazolidines |
DE2451160A1 (de) * | 1973-10-30 | 1975-05-07 | Du Pont | 3-pyrazolidinone und pyrazolidine |
US3976660A (en) * | 1974-08-15 | 1976-08-24 | E. R. Squibb & Sons, Inc. | Pyrrolidine derivatives |
DE2527989A1 (de) | 1975-06-24 | 1977-01-27 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4033989A (en) * | 1975-09-17 | 1977-07-05 | The Upjohn Company | 9-Deoxy-PGF2 Analogs |
US4003911A (en) | 1975-09-26 | 1977-01-18 | E. I. Du Pont De Nemours And Company | Selected 3-pyrrolidinones and 2,4-pyrrolidindiones |
US4090019A (en) | 1976-05-10 | 1978-05-16 | Minnesota Mining And Manufacturing Company | Geminal prostaglandin analogs |
US4211876A (en) | 1979-06-13 | 1980-07-08 | E. I. Du Pont De Nemours And Company | 3-Pyrazolidinone carboxamides |
US4753945A (en) | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
US5091431A (en) | 1988-02-08 | 1992-02-25 | Schering Corporation | Phosphodiesterase inhibitors |
US5010086A (en) | 1990-02-28 | 1991-04-23 | Sterling Drug Inc. | Imidazopyridines, compositions and use |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
US5605814A (en) | 1993-08-31 | 1997-02-25 | Merck Frosst Canada Inc. | DNA encoding human prostaglandin receptor EP2 |
GB9514465D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6143746A (en) | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9514160D0 (en) | 1994-07-25 | 1995-09-13 | Zeneca Ltd | Aromatic compounds |
GB9417532D0 (en) | 1994-08-31 | 1994-10-19 | Zeneca Ltd | Aromatic compounds |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
TW434240B (en) | 1995-06-20 | 2001-05-16 | Zeneca Ltd | Aromatic compounds, preparation thereof and pharmaceutical composition comprising same |
TW502026B (en) | 1995-06-20 | 2002-09-11 | Zeneca Ltd | Aromatic compounds useful as antagonists of e-type prostaglandins, processes for the preparation thereof, pharmaceutical compositions comprising the compounds, and intermediates |
EP0752421B1 (de) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituierte aromatische Verbindungen, die drei (Het)aryl-Ringe enthalten, deren Herstellung und deren Verwendung als Prostaglandin-E2-(PGE2)-Antagonisten |
GB9514464D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
EA199800907A1 (ru) | 1996-05-10 | 1999-04-29 | Айкос Корпорейшн | Производные карболина |
JP2001505198A (ja) | 1996-11-20 | 2001-04-17 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Pde阻害剤としての置換ジヒドロベンゾフラン |
UA59384C2 (uk) | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
AT404730B (de) * | 1997-04-07 | 1999-02-25 | Holderchem Ag | Acryl-copolymere und polymerzusammensetzungen sowie deren verwendung als additive oder beimischungen zur verbesserung der eigenschaften von dispersionen und baustoffen |
US6043252A (en) | 1997-05-05 | 2000-03-28 | Icos Corporation | Carboline derivatives |
JP2001510827A (ja) | 1997-07-25 | 2001-08-07 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 置換6−フェニルフェナントリジン |
US6006735A (en) | 1997-09-12 | 1999-12-28 | Park Industries, Inc. | Automated stoneworking system and method |
US6127363A (en) | 1997-10-28 | 2000-10-03 | Vivus, Inc. | Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6156753A (en) | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
GB9725953D0 (en) | 1997-12-08 | 1998-02-04 | Pfizer Ltd | Compounds useful in therapy |
US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
GB9822238D0 (en) | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
AP2001002357A0 (en) * | 1999-12-22 | 2001-12-31 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis. |
ATE315022T1 (de) * | 2001-07-16 | 2006-02-15 | Hoffmann La Roche | Prostaglandinanaloga als ep4-rezeptoragonisten |
US7335680B2 (en) * | 2001-12-20 | 2008-02-26 | Laboratoires Serono Sa | Pyrrolidine derivatives as prostaglandin modulators |
-
2002
- 2002-12-19 US US10/499,346 patent/US7335680B2/en not_active Expired - Fee Related
- 2002-12-19 ES ES02793091T patent/ES2337887T3/es not_active Expired - Lifetime
- 2002-12-19 CA CA2469075A patent/CA2469075C/en not_active Expired - Fee Related
- 2002-12-19 AT AT02793091T patent/ATE455758T1/de not_active IP Right Cessation
- 2002-12-19 WO PCT/EP2002/014593 patent/WO2003053923A2/en active Application Filing
- 2002-12-19 EP EP02793091A patent/EP1458679B1/de not_active Expired - Lifetime
- 2002-12-19 JP JP2003554640A patent/JP4554931B2/ja not_active Expired - Fee Related
- 2002-12-19 AU AU2002358772A patent/AU2002358772B2/en not_active Ceased
- 2002-12-19 IL IL16260202A patent/IL162602A0/xx unknown
- 2002-12-19 DE DE60235198T patent/DE60235198D1/de not_active Expired - Lifetime
-
2004
- 2004-06-17 IL IL162602A patent/IL162602A/en not_active IP Right Cessation
-
2007
- 2007-11-21 US US11/943,684 patent/US7635713B2/en not_active Expired - Fee Related
-
2009
- 2009-02-19 AU AU2009200663A patent/AU2009200663B2/en not_active Ceased
- 2009-08-03 US US12/534,292 patent/US8058305B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1458679A2 (de) | 2004-09-22 |
CA2469075A1 (en) | 2003-07-03 |
US7635713B2 (en) | 2009-12-22 |
ATE455758T1 (de) | 2010-02-15 |
AU2009200663B2 (en) | 2011-09-15 |
AU2002358772A1 (en) | 2003-07-09 |
ES2337887T3 (es) | 2010-04-30 |
AU2002358772B2 (en) | 2008-11-20 |
WO2003053923A3 (en) | 2004-01-29 |
AU2009200663A1 (en) | 2009-03-12 |
CA2469075C (en) | 2011-09-13 |
US8058305B2 (en) | 2011-11-15 |
JP4554931B2 (ja) | 2010-09-29 |
IL162602A (en) | 2011-07-31 |
US20050176800A1 (en) | 2005-08-11 |
EP1458679B1 (de) | 2010-01-20 |
US20090292000A1 (en) | 2009-11-26 |
US7335680B2 (en) | 2008-02-26 |
JP2005517665A (ja) | 2005-06-16 |
US20080114051A1 (en) | 2008-05-15 |
IL162602A0 (en) | 2005-11-20 |
WO2003053923A2 (en) | 2003-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60235198D1 (de) | Pyrrolidin-derivatie als prostaglandin-modulatoren | |
IL161581A (en) | Pyrazolidinone derivatives and their use | |
MA27556A1 (fr) | Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete | |
MA27548A1 (fr) | Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete. | |
NO20030895D0 (no) | Ny anvendelse av dipeptidyl peptidase IV inhibitorer | |
DE602004024572D1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
ATE463492T1 (de) | Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes | |
EP1408986A4 (de) | Proteomimetische verbindungen und verfahren | |
DE60333387D1 (de) | Triazolopyridazine als proteinkinase-inhibitoren | |
DE60314603D1 (de) | Zusammensetzungen brauchbar als protein-kinase- inhibitoren | |
EP1385508A4 (de) | Dipeptidylpeptidase-hemmer für die behandlung oder prävention von diabetes | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
NO20040331L (no) | Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel | |
DE60332433D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
DE60330485D1 (de) | Zur behandlung von diabetes | |
UA48939C2 (uk) | Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки | |
ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
DE69729125D1 (de) | Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese | |
WO2003103604A3 (en) | GAMMA LACTAMES USED AS PROSTAGLANDIN AGONISTS AND THEIR USE | |
EA200501710A1 (ru) | Замещённые карбоновые кислоты | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
DK1456380T3 (da) | SMAD7-inhibitorer til behandling af CNS-sygdomme | |
ATE452884T1 (de) | Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase | |
EA200200518A1 (ru) | Способ и композиция для лечения заболеваний легких |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |